Phase II studies have suggested that vinorelbine (V) plus gemcitabine (G) treatment has a
similar response rate and better toxicity profile than cisplatin-based combination …

In 2009, vinflunine was introduced as a second-line treatment to be used after the failure of
platinum therapy in patients with metastatic urothelial carcinoma (mUC). The present study …

Ninety patients with stage-3 non-small cell lung cancer were given vindesine (3 mg/sq m)
plus mitomycin (10 mg/sq m). Data on response are available for 84 adequately treated …

From March 1981 to January 1984, 116 patienst with advanced non-small-cell carcinoma of
the lung (NSCCL) were randomly assigned to 3 combinations as follows: CDDP+ DVA …

Background The purpose of this study was to compare quality of life and overall toxicity in
patients with advanced non-small-cell lung cancer (NSCLC) treated with vinorelbine …

We evaluated the efficacy and toxicity of the novel combination of ifosfamide (IFX) and
vinorelbine (VNB) as first-line chemotherapy in patients with stage IIIB and IV non-small cell …

Objective: A phase II study was conducted to evaluate the efficacy and toxicity of vinorelbine–
carboplatin (VNB–C) combination as a salvage treatment in patients with advanced non …

Vinflunine is a novel third-generation bifluorinated semisynthetic vinca alkaloid that has
been shown to have activity against a variety of solid tumor types including advanced …

Purpose The purpose of the study was to assess the possible benefit of the combination
vinorelbine (NVB)-cisplatin (DDP) in comparison with NVB alone in advanced non-small cell …

Patients with advanced nonsmall-cell lung cancer (NSCLC), good performance status, and
no prior chemotherapy were randomized to receive one of three regimens: intravenous …